NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
NextCure, Inc. announced that the FDA has granted Fast Track designation to its investigational therapy SIM0505 for treating platinum-resistant ovarian cancer. SIM0505 is an antibody drug conjugate targeting Cadherin-6, currently in Phase 1 trials, with dose optimization expected in Q2 2026 and Phase 1 data to be presented at ASCO 2026. The Fast Tr…